Riboflavin for Health & Longevity - Quick Reference Sheet

Riboflavin for Health & Longevity

Created on 07/07/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Riboflavin is an essential, inexpensive, and very safe vitamin central to cellular energy and activating other B vitamins. Correcting a shortfall reliably restores health. Its strongest targeted use is preventing migraine in adults at high daily doses. In people with a specific folate-related gene variant, it may help lower blood pressure. Broader energy and longevity claims outpace the evidence. (Full Review)

Protocol

Migraine Prevention
400 mg/day
Once daily with a meal; trial for at least 8–12 weeks
General Adequacy
10–25 mg/day
RDA ~1.1–1.3 mg/day; wide safety margin
MTHFR Blood Pressure
~1.6 mg/day
TT-genotype adults; cofactor repletion
Time to effect
Migraine Prevention
4–12 weeks
Full effect may need up to 3 months
Deficiency Correction
Days to weeks
Functional signs resolve
Blood Pressure
4–8 weeks
In TT-genotype adults

Benefits

Contraindications
  • Known hypersensitivity to riboflavin
Key Interactions
  • Tricyclic antidepressants (amitriptyline, imipramine)
  • Phenothiazine antipsychotics (chlorpromazine, thioridazine)
  • Probenecid
  • Antineoplastic agents (doxorubicin)
  • Chronic high alcohol intake

Risk & Side Effects

  • High: Bright yellow-orange urine
  • Low: Gastrointestinal discomfort; interference with certain laboratory assays
  • Speculative: Photosensitization and oxidative stress under light; masking of a concurrent B12 deficiency

Monitoring

Marker Target Why
Erythrocyte glutathione reductase activation coefficient (EGRAC) ≤ 1.20 (adequate); 1.20–1.40 marginal Gold-standard functional test of riboflavin status
Plasma/serum riboflavin ~4–24 nmol/L (adequate) Direct measure of circulating vitamin
Homocysteine ≤ 7–8 µmol/L Tracks the metabolic effect relevant to MTHFR carriers
Blood pressure < 120/80 mmHg Primary outcome for the MTHFR 677TT rationale
MTHFR C677T genotype Identifies TT carriers Determines who is likely to respond to the metabolic/blood-pressure use
Complete blood count (hemoglobin, MCV) Hemoglobin ~13.5–15 g/dL; MCV 85–92 fL Detects anemia that riboflavin repletion can help correct

Cadence: Baseline, then recheck at 8–12 weeks; every 6–12 months if continued. Blood pressure in TT-genotype users checked more frequently (baseline, 4–8 weeks, periodically).

Qualitative Assessment

  • Migraine frequency, duration, and severity tracked in a simple headache diary
  • Day-to-day energy and exertional tolerance
  • Resolution of deficiency signs (cracked lip corners, sore or inflamed tongue, skin changes)
  • Bright yellow-orange urine as a practical, harmless marker that a dose was taken and absorbed
  • General sense of well-being and, where relevant, mood